Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517369 | 0.91 | TRPC5 (0.67) | TRPC5ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL20752038 | 0.90 | TRPC5 (0.68) | TRPC5ALDH1A1HPGDRXFP1POLB | |
| SCHEMBL20752039 | 0.88 | TRPC5 (0.53) | TRPC5ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL20752030 | 0.88 | TRPC5 (0.53) | TRPC5ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL17501656 | 0.88 | TRPC5 (0.63) | TRPC5ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL20752021 | 0.81 | TRPC5 (0.64) | TRPC5 | |
| SCHEMBL17501674 | 0.80 | TRPC5 (1.00) | TRPC5RXFP1 | |
| SCHEMBL17522760 | 0.80 | TRPC5 (0.55) | TRPC5ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL20752037 | 0.74 | TRPC5 (0.53) | TRPC5ALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL20752020 | 0.73 | TRPC5 (0.63) | TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180318-B1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | HYDRA BIOSCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3180318-B1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | HYDRA BIOSCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| EP-3180318-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016023826-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023826-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | TRPC5, HTR5A, TRPV5 | TRPC5 1/4885ALDH1A1 1768/4885HPGD 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.